胸腺肽α_1联合拉米夫定治疗慢性乙型肝炎

Therapeutic Efficacy of Thymosin-α_1 Combined with Lamivudine on Patients with Chronic Hepatitis B

目的:观察胸腺肽α1联合拉米夫定治疗慢性乙型肝炎的疗效。方法:70例HBV DNA、HBeAg阳性的慢性乙型肝炎患者随机分为两组:治疗组与对照组,每组35例。对照组采用拉米夫定治疗;治疗组采用拉米夫定联合胸腺肽α1治疗。结果:治疗组HBeAg阴转率、ALT复常率分别为60.6%(20/33)、78.8%(26/33),均明显高于对照组的34.3%(12/35)、54.3%(19/35)(P均<0.05);治疗组HBV DNA阴转率与对照组之间差异无统计学意义(P>0.05)。治疗过程中两组均未发现HBV前C区变异株;HBV YMDD变异株:治疗组仅有1例(3.03%),对照组有8例(22.8%),两组比较,差异有统计学意义(P<0.05)。结论:拉米夫定联合胸腺肽α1治疗慢性乙型肝炎疗效较好,值得临床应用。

Objective：To observe the efficacy of alpha-1-thymosin combined with Lamivudine in the patients with chronic hepatitis B. Methods：Seventy patients with chronic hepatitis B were enrolled randomly into two groups. Thirty-five patients received alpha-1-thymosin 1.6 mg subcutaneous injection combined with 100 mg Lamivudine orally （treated group）,the other patients were given 100 mg Lamivudine alone （control group）. Results：The serum negative rate of HBeAg and the ALT normalization rates were 60. 6% （20/33） and 78. 8% （26/33）, respectively, in the treated group and were significantly higher than those （34.3% and 54.3%）in the control group with P value 〈0.05. The serum negative rate of HBV DNA of the two groups were not different significantly,P〉0.05. HBV precore region variability was not found in two groups during treatment. However,22.8% of patients in the control group had YMDD variant HBV as compared with 3.03% in the treated group,and P value was 〈0.05. Conclusion： Thymosin-α1 combined with Lamivudine is effective for the patients with chronic hepatitis B and is valuable to be used in clinical.